No Data
Medical stocks collectively surged! Bullish news has arrived, the medical sector welcomes a catalyst.
The medical sector with lagging growth finally sees a catalyst! Analysis believes that for medical institutions, prepayment of medical insurance funds helps optimize and improve the daily operation cash flow and financial pressure of medical institutions, reducing the potential receivables and bad debt risks caused by unpaid medical insurance expenses. For medical insurance, it enhances the settlement efficiency and encourages the active diagnosis and treatment enthusiasm of medical institutions.
Hong Kong stocks abnormal fluctuations | CRO concept stocks lead the gains, institutions believe that the future performance recovery is worth looking forward to. The listing of innovative drugs in the United States has demands for reducing research and d
CRO concept stocks lead the gains. As of the press release, wuxi xdc (02268) rose by 11.29% to HK$27.6; wuxi apptec (02359) fell by 4.07% to HK$58.8; wuxi bio (02269) rose by 3.09% to HK$17.34; tigermed (03347) rose by 3.05% to HK$38.9.
wuxi bio (02269.HK): Introducing a one-stop solution for animal medicine to open up new markets and contribute to incremental volume.
In early November, wuxi bio announced the launch of PawBio, a one-stop solution for animal health biologics. We believe that as a leading company in the human biologics CDMO industry, wuxi bio has rich project experience, leading service quality, and high customer recognition.
Trump Government Likely to Still Pass Biosecure Act -- Market Talk
Abnormal movements | The CRO concept is generally rising, with medical insurance negotiations supporting innovative drugs. Global biomedical financing will rebound in an environment of interest rate cuts.
The concept of CRO is generally on the rise. As of the time of publication, Asymchem Laboratories rose by 4.95%, to 59.4 Hong Kong dollars; Tigermed rose by 5.21%, to 38.35 Hong Kong dollars; WuXi AppTec rose by 3.69%, to 53.4 Hong Kong dollars.
Mainland medical insurance pharmaceutical catalog adjustment negotiations are expected to end, and the new version of the catalog is expected to be released by the end of the month.
According to a report by the People's Daily, following the established work arrangements, from October 27th to 30th, under the organization of the National Medical Insurance Bureau, 25 negotiating experts from various provincial medical insurance departments conducted on-site negotiations and bidding with 127 enterprises, involving 162 types of pharmaceuticals, including 117 types of pharmaceuticals outside the medical insurance catalog and 45 types of pharmaceuticals within the negotiated renewal in the medical insurance catalog. This year's on-site negotiation work progressed smoothly and steadily, with overall results basically consistent with previous years, meeting expectations. The new version of the medical insurance pharmaceutical catalog after the “expansion” is expected to be released to the public at the end of November, and will be officially implemented starting next year. Relevant to the National Medical Insurance Administration's Pharmaceutical Service Management Department.
No Data
No Data